August 24, 2016 1:33 AM ET

Professional Services

Company Overview of MaRS Innovation Inc.

Company Overview

MaRS Innovation Inc. provides commercial services, early-stage funding resources, and broker deals with industry and private investors. Its services include strategy development, business development, intellectual property, project management, operational, marketing resources, human resources, financial management, investor relations, and next round funding. The company offers services to global markets through industry partnerships, licensing, or start-up companies. MaRS Innovation Inc. was founded in 2008 and is based in Toronto, Canada.

MaRS Centre

West Tower

661 University Avenue

Suite 465

Toronto, ON M5G 1M1

Canada

Founded in 2008

Phone:

647-260-7869

Key Executives for MaRS Innovation Inc.

Chief Executive Officer, President and Director
Age: 67
Head of Clean Technologies
Director of Marketing & Communications
Senior Director of Strategic Planning
Director of Intellectual Property
Compensation as of Fiscal Year 2016.

MaRS Innovation Inc. Key Developments

The Ontario Government, University of Toronto, and MaRS Discovery District Announce Collaboration with Janssen to Launch Johnson & Johnson Innovation, JLABS Incubator Model in Toronto

The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto. The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies. As the first JLABS to open outside the United States, JLABS at Toronto joins a network of life science facilities that are based throughout the United States in San Diego, San Francisco, South San Francisco, Boston and Houston. These facilities are home to over 100 early-stage companies advancing bio/pharmaceutical, medical device, consumer and digital health programs. JLABS at Toronto will be located at MaRS Discovery District, occupying one floor of the West Tower. JLABS at Toronto will provide startups with many of the advantages of being part of an established innovation centre - such as access to talent and mentors, large existing firms and research universities, capital and convergence opportunities with other sectors. When complete, the 40,000-square foot facility will include cutting-edge, modular and scalable lab space, equipment, with access to scientific, industry and capital funding experts. JLABS at Toronto is a collaboration among Johnson & Johnson Innovation, The University of Toronto, MaRS Discovery District, Janssen Inc., MaRS Innovation, and the Government of Ontario. Hospital participants include: Centre for Addiction and Mental Health, The Hospital for Sick Children (SickKids), Sinai Health System, St. Michael's Hospital, Sunnybrook Health Sciences Centre, and University Health Network. Construction of JLABS at Toronto will begin in 2015, and is expected to be ready for occupancy by spring 2016. Over the coming months, best practices pioneered at other JLABS will be adopted to accelerate the impact and success of this new collaboration.

Encycle Therapeutics Inc. Announces Partnership with MaRS Innovation to Develop Molecule to Tackle Inflammatory Bowel Disease

Encycle Therapeutics Inc. in partnership with MaRS Innovation which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease. To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR), the Université de Montréal (UdeM) and MaRS Innovation. The agreement brings a significant investment to fund Encycle Therapeutics' development work, giving IRICoR an equity position and expanding MaRS Innovation's equity stake. Cumulatively, Encycle Therapeutics has secured more than $2.5 million to advance its drug development platform. The partnership will fund and deploy a number of experienced medicinal chemists at UdeM's Institute for Research in Immunology and Cancer (IRIC) to optimize Encycle Therapeutics' lead molecule. Additional studies will be conducted at the biopharmacy platform of the Faculty of Pharmacy of the UdeM, while Encycle Therapeutics conducts other project-related activities, including pre-clinical efficacy studies.

Similar Private Companies By Industry

Company Name Region
1504607 Ontario Inc. Americas
49-97 Capital Partners Americas
500 Staffing Services Ltd ,The Americas
511670 Alberta Ltd Americas
A-1 Personnel Resources, Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 31, 2016
ScarX Therapeutics Inc.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MaRS Innovation Inc., please visit www.marsinnovation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.